Apollo Hospitals adopts Microsoft AI assistants
Apollo Hospitals will adopt four AI assistants as part of its new collaboration with Microsoft.
The technology giant said in a statement that it will help the hospital group develop and implement its AI roadmap, which will focus on expanding Apollo’s telehealth platform across the globe and building new technology solutions.
This engagement is part of a series of strategic partnerships that Microsoft has entered into in the new year in India. It recently pledged to invest $3 billion in cloud infrastructure and artificial intelligence in the country over the next two years.
Along with the Indian government, Microsoft has partnered with major industry players, including public broadband provider RailTel, conglomerate Mahindra Group, finance company Bajaj Finance Ltd., and education technology platform upGrad, to “build a thriving AI ecosystem.” In India.
The telehealth system at National Taiwan University Hospital incorporates artificial intelligence
National Taiwan University Hospital (NTUH) has integrated speech-to-text AI into its telehealth platform.
The intelligent voice system on NTUH’s 4G telehealth platform is based on voice recognition technology provided by Chunghwa Telecom, the largest telecommunications service provider in Taiwan. Chunghwa’s technology, intended for healthcare, is optimized on audio data collected by NTUH’s Telehealth Center.
The AI-based voice recognition feature can translate a speaker’s mixed usage of languages, such as Mandarin, English, Taiwanese, and dialect Chinese, as well as medical terms and drug names into bilingual.
This new feature also integrates NTUH’s emergency event forecasting technology to forecast potential emergency events within two weeks with approximately 90% accuracy.
NEC announces new partnership for AI in pathology
Japan-based NEC has partnered with a local AI company to develop digital pathology solutions.
NEC said in a statement that it will work with Biomy on enhancing its cloud-based automated digital disease analysis platform DeepPathFinder to discover new disease biomarkers.
They will later provide the enhanced digital pathology platform to pharmaceutical and biotechnology companies and academic institutions.
